Friday January 26, 2018 0 comments
DENVER -- The Colorado BioScience Association (CBSA) will host more than 80 medtech leaders on Jan. 30 to discuss industry metrics, shifting business models, M&A trends, FDA reform and the efforts to seek a permanent repeal of the medical device excise tax during the 2018 CBSA Medical Device Symposium.
The annual event gives leaders of Colorado’s medical device industry an in-depth look at economic trends and public policy shaping the U.S. sector, which experienced its best year-on-year growth since the 2008 financial crisis.
“In a changing healthcare landscape, it’s critical for our established and emerging companies to get early insights on the new developments, policies and trends impacting the device sector,” said April Giles, CBSA president and CEO.
“We’re proud to bring Colorado CEOs together to share ideas and learn from speakers who monitor and advocate for the medical device industry on a national level.”
“Following this week’s two-year suspension of the medical device excise tax, retroactive to January 1, 2018, we remain committed to a full and permanent repeal of the device tax,” said Clayton Hall, VP of government affairs for the Medical Device Manufacturing Association.
“We’ll talk about where we think Congress is headed this year, the upcoming elections, and our ongoing work with the FDA and CMS to create a more predictable regulatory and reimbursement climate for medical technology innovation.”
Additionally, CBSA said speakers and panelists will provide their perspectives on developing and launching new products and the convergence of digital health and medical technology in the state during the symposium, at the Westin Westminster.
Sponsors of the symposium include: Snell & Wilmer, lead sponsor; EY and Fitzsimons Redevelopment Authority, supporting sponsors.
The conference will be held from 1-5 p.m. at the Westin Westminster – Lakehouse, 10600 Westminster Blvd. Registration is $50 for CBSA members and $100 for non-members.